New Delhi, March 04, 2022: WuXi STA – a subsidiary of WuXi AppTec – today announced that its drug product…
State-of-the-art facility expands WuXi STA's capacity and capability for this novel modality, providing a one-stop shop from preclinical to commercial …
STA will accelerate process R&D and manufacturing of late phase and commercial targets New Delhi, March 25, 2019: STA Pharmaceutical…
Agreement follows the recent opening of WuXi STA’s oligonucleotide R&D labs in China and the USA. Shanghai, May 03, 2018: STA…